Boston Scientific Corporation (BSX) Stock Analysis & Investment Frameworks
Boston Scientific Corporation (BSX) stock analysis on Invetso. Review Boston Scientific Corporation’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Boston Scientific Corporation Company Overview
- Exchange: New York Stock Exchange
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
Boston Scientific Corporation Key Financial Metrics
- Market Cap: $62.42B
- Revenue: $20.07B
- P/E Ratio: 21.64
- ROE: 13.87%
- ROIC: 10.46%
- Dividend Yield: N/A
About Boston Scientific Corporation
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Boston Scientific Corporation Investment Frameworks
Invetso analyzes Boston Scientific Corporation (BSX) across the following frameworks:
- Boston Scientific Corporation 10Y Growth Potential
- Boston Scientific Corporation Scenario Analysis
- Boston Scientific Corporation Risks & Opportunities
- Boston Scientific Corporation Economic Moat
- Boston Scientific Corporation Business Model
- Boston Scientific Corporation Management
- Boston Scientific Corporation SWOT Analysis
- Boston Scientific Corporation Porter's 5 Forces
- Boston Scientific Corporation PESTLE Analysis
- Boston Scientific Corporation ESG Analysis

